BridgeBio Pharma Inc. (BBIO)
34.83
0.92 (2.71%)
At close: Apr 14, 2025, 3:46 PM
2.71% (1D)
| Bid | 34.59 |
| Market Cap | 6.62B |
| Revenue (ttm) | 221.9M |
| Net Income (ttm) | -535.76M |
| EPS (ttm) | -2.88 |
| PE Ratio (ttm) | -12.09 |
| Forward PE | -10.23 |
| Analyst | Buy |
| Ask | 35 |
| Volume | 977,120 |
| Avg. Volume (20D) | 3,095,824 |
| Open | 34.48 |
| Previous Close | 33.91 |
| Day's Range | 33.58 - 35.02 |
| 52-Week Range | 21.62 - 39.47 |
| Beta | 1.08 |
About BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-car...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2019
Employees 725
Stock Exchange NASDAQ
Ticker Symbol BBIO
Website https://www.bridgebio.com
Analyst Forecast
According to 12 analyst ratings, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is $49, which is an increase of 40.70% from the latest price.
Stock ForecastsNext Earnings Release
BridgeBio Pharma Inc. is scheduled to release its earnings on May 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.63%
BridgeBio Pharma shares are trading lower after th...
Unlock content with
Pro Subscription
4 months ago
+16.1%
BridgeBio Pharma shares are trading higher after the company announced that the FDA approved Attruby to treat adults with ATTR-CM. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $43 to $49.
